Advanced search
Publication Cover
Current Medical Research and Opinion Volume 30, 2014 - Issue 10
Submit an article Journal homepage
935
Views
1
CrossRef citations to date
0
Altmetric
Response to Letter to the Editor

Response to Becher and Strohner comment regarding Baker DL et al. Evaluation of two commercial omalizumab/free IgE immunoassays: implications of use during therapy. CMRO 2014;30:913-22

Dana L. BakerDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USA
,
Kun PengDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USA
,
Melissa CheuDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USA
&
Saloumeh Kadkhodayan FischerDepartment of Assay Development and Technology Genentech 1 DNA Way, South San Francisco CA 94080USACorrespondence[email protected]
Pages 1927-1929 | Published online: 07 Jul 2014

Figures & data

Figure 1. a) A set of 12 omalizumab-naïve samples with various IgE levels was utilized for total and free IgE measurements using Genentech or the two commercial assays. Compared with the free IgE results obtained using the Genentech and ViraCor-IBT assays, 3 samples (#5, #52 and #56) under recovered significantly in the BioTeZ assay. (b) All 12 samples were omalizumabnaïve and therefore should not have measurable levels of omalizumab. However, the same 3 samples (#5, #52 and #56) yielded measurable false-positive levels of omalizumab in the BioTeZ omalizumab assay.

Figure 1. a) A set of 12 omalizumab-naïve samples with various IgE levels was utilized for total and free IgE measurements using Genentech or the two commercial assays. Compared with the free IgE results obtained using the Genentech and ViraCor-IBT assays, 3 samples (#5, #52 and #56) under recovered significantly in the BioTeZ assay. (b) All 12 samples were omalizumabnaïve and therefore should not have measurable levels of omalizumab. However, the same 3 samples (#5, #52 and #56) yielded measurable false-positive levels of omalizumab in the BioTeZ omalizumab assay.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.